ID

DB00256|APRD00565|EXPT01049|

名称

Lymecycline

描述

Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.[L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]

cas号

992-21-2

唯一标识码

7D6EM3S13P

状态

solid

组

approved,investigational,

指示

Lymecycline is used for the treatment of acne in addition to other susceptible infections; propionibacterium is often the cause of acne.[L13880] Some of the infections that can be treated with lymecycline include upper respiratory tract infections, urinary tract infections, bronchitis, chlamydial infections, and rickettsial infections.[L13883]

药效学

Lymecycline, like other tetracyclines, exerts bacteriostatic actions on intracellular and extracellular bacteria, treating susceptible bacterial infections.[L13883] It has been shown to be safe and effective in the treatment of moderate to severe acne.[A203249] It is important to note that like other tetracyclines, lymecycline may cause esophageal irritation and ulceration, which can be prevented by drinking adequate fluids during administration. It also has the potential to cause photosensitivity. Lymecycline can lead to renal tubular acidosis or hepatic toxicity. It is not recommended to administer this drug in patients with renal disease or severe hepatic disease.[L13880,L13883]

作用机制

Normally, the ribosome synthesizes proteins through the binding of aminoacyl-tRNA to the mRNA-ribosome complex. Lymecycline binds to the 30S ribosomal subunit, preventing amino-acyl tRNA from binding to the A site of the ribosome, which prevents the elongation of polypeptide chains.[A19429,A174040,L13880] This results in bacteriostatic actions, treating various infections.

毒性

The oral LD50 of lymecycline in rats is 3200 mg/kg.[L13913] Overdoses with lymecycline are rare. In the case of an overdose, gastric lavage should be performed immediately. Provide supportive treatment and maintain fluid balance.[L13883]

代谢

吸收

Lymecycline is 77-88% absorbed after oral administration with a relative bioavailability of 70%.[A203258] The Cmax of lymecycline is 2.1 mg/L and is achieved about 3 hours after administration.[A1424] The AUC is 21.9 ± 4.3 mg·h/L.[A1424]

半衰期

The half-life of lymecycline is approximately 8 hours.[A1424]

分类

description:This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
direct-parent:Tetracyclines
kingdom:Organic compounds
superclass:Phenylpropanoids and polyketides
class:Tetracyclines
subclass:
alternative-parent:1-hydroxy-2-unsubstituted benzenoids
alternative-parent:1-hydroxy-4-unsubstituted benzenoids
alternative-parent:Amino acids
alternative-parent:Amino fatty acids
alternative-parent:Anthracenecarboxylic acids and derivatives
alternative-parent:Aralkylamines
alternative-parent:Aryl ketones
alternative-parent:Carboxylic acids
alternative-parent:Cyclohexenones
alternative-parent:Dialkylamines
alternative-parent:Enols
alternative-parent:Hydrocarbon derivatives
alternative-parent:Hydroxy fatty acids
alternative-parent:L-alpha-amino acids
alternative-parent:Medium-chain fatty acids
alternative-parent:Monoalkylamines
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Naphthacenes
alternative-parent:Organic oxides
alternative-parent:Organopnictogen compounds
alternative-parent:Polyols
alternative-parent:Secondary carboxylic acid amides
alternative-parent:Tertiary alcohols
alternative-parent:Tetralins
alternative-parent:Trialkylamines
alternative-parent:Vinylogous acids
substituent:1-hydroxy-2-unsubstituted benzenoid
substituent:1-hydroxy-4-unsubstituted benzenoid
substituent:Alcohol
substituent:Alpha-amino acid
substituent:Alpha-amino acid or derivatives
substituent:Amine
substituent:Amino acid
substituent:Amino acid or derivatives
substituent:Amino fatty acid
substituent:Anthracene carboxylic acid or derivatives
substituent:Aralkylamine
substituent:Aromatic homopolycyclic compound
substituent:Aryl ketone
substituent:Benzenoid
substituent:Carbonyl group
substituent:Carboxamide group
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Cyclohexenone
substituent:Enol
substituent:Fatty acyl
substituent:Hydrocarbon derivative
substituent:Hydroxy fatty acid
substituent:Ketone
substituent:L-alpha-amino acid
substituent:Medium-chain fatty acid
substituent:Monocarboxylic acid or derivatives
substituent:Naphthacene
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Polyol
substituent:Primary aliphatic amine
substituent:Primary amine
substituent:Secondary aliphatic amine
substituent:Secondary amine
substituent:Secondary carboxylic acid amide
substituent:Tertiary alcohol
substituent:Tertiary aliphatic amine
substituent:Tertiary amine
substituent:Tetracene
substituent:Tetracycline
substituent:Tetralin
substituent:Vinylogous acid

消除途径

Lymecycline is 25% eliminated in the urine.[A1424] Based on being a member of the tetracycline drug class, fecal elimination is likely another route of elimination.[A203366]

种类

Agents that produce neuromuscular block (indirect)

Anti-Bacterial Agents
D000900
Anti-Infective Agents
D000890
Antibacterials for Systemic Use

Antiinfectives for Systemic Use

Naphthacenes
D009279
Tetracyclines
D013754

盐类

蛋白质结合

清除

Lymecycline is partially cleared by the kidneys, like other tetracyclines.[A203366]

同义词

language:english; code:; name;(+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide
language:spanish; code:inn; name;Limeciclina
language:english; code:inn; name;Lymecycline
language:latin; code:inn; name;Lymecyclinum
language:english; code:; name;N-Lysinomethyltetracycline
language:english; code:; name;N2-(((+)-5-Amino-5-carboxypentylamino)methyl)tetracycline
language:english; code:; name;N6-((4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamido)methyl)lysine
language:english; code:; name;Tetracycline-L-methylene lysine
language:english; code:; name;Tetracycline-L-methylenelysine

国际品牌

EficiclinaTetralisalTetralysal

配送量

Lymecycline is lipophilic and easily crosses the cell membrane and passively diffuses through bacterial porin channels.[A1424,A19429] As a second-generation tetracycline, the concentration in the bile ranges from 10 to 25 times higher than plasma concentration.[A1424,A203366] In general, the volume of distribution of tetracyclines ranges from 1.3–1.7 L/kg or 100–130 L.[A1424]

产品

混合物

包装者

name:Proter SPA
url:
name:Galderma Laboratories
url:http://www.galderma.com

生产者

generic:否; url:; name;Lederle laboratories div american cyanamid co

价格

受影响的生物体

Enteric bacteria and other eubacteria

剂量

form:Capsule
route:Oral
strength:300 mg
form:Capsule
route:Oral
strength:408 MG
form:Capsule
route:Oral
strength:150 MG
form:Injection
route:Intramuscular
strength:100 MG
form:Capsule, coated
route:Oral
strength:300 mg

atc代码

Tetracyclines
TETRACYCLINES
ANTIBACTERIALS FOR SYSTEMIC USE
ANTIINFECTIVES FOR SYSTEMIC USE
Tetracyclines
TETRACYCLINES
ANTIBACTERIALS FOR SYSTEMIC USE
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

化学品安全技术说明书

专利

食物相互作用

Take with or without food.

药物相互作用

DB00202
The therapeutic efficacy of Succinylcholine can be increased when used in combination with Lymecycline.
DB00416
The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Lymecycline.
DB00483
The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Lymecycline.
DB00565
The therapeutic efficacy of Cisatracurium can be increased when used in combination with Lymecycline.
DB00728
The therapeutic efficacy of Rocuronium can be increased when used in combination with Lymecycline.
DB00732
The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Lymecycline.
DB01135
The therapeutic efficacy of Doxacurium can be increased when used in combination with Lymecycline.
DB01226
The therapeutic efficacy of Mivacurium can be increased when used in combination with Lymecycline.
DB01245
The therapeutic efficacy of Decamethonium can be increased when used in combination with Lymecycline.
DB01336
The therapeutic efficacy of Metocurine can be increased when used in combination with Lymecycline.
DB01337
The therapeutic efficacy of Pancuronium can be increased when used in combination with Lymecycline.
DB01338
The therapeutic efficacy of Pipecuronium can be increased when used in combination with Lymecycline.
DB01339
The therapeutic efficacy of Vecuronium can be increased when used in combination with Lymecycline.
DB04834
The therapeutic efficacy of Rapacuronium can be increased when used in combination with Lymecycline.
DB11156
The therapeutic efficacy of Pyrantel can be increased when used in combination with Lymecycline.
DB12989
The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Lymecycline.
DB13295
The therapeutic efficacy of Atracurium can be increased when used in combination with Lymecycline.
DB13584
The therapeutic efficacy of Gallamine can be increased when used in combination with Lymecycline.
DB13648
The therapeutic efficacy of Alcuronium can be increased when used in combination with Lymecycline.
DB01199
The therapeutic efficacy of Tubocurarine can be increased when used in combination with Lymecycline.
DB01294
The serum concentration of Lymecycline can be decreased when it is combined with Bismuth subsalicylate.
DB00657
Lymecycline may increase the neuromuscular blocking activities of Mecamylamine.
DB05528
Lymecycline may increase the hepatotoxic activities of Mipomersen.
DB00881
Quinapril can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00364
Sucralfate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09146
The serum concentration of Lymecycline can be decreased when it is combined with Iron sucrose.
DB00301
The therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Lymecycline.
DB00319
The therapeutic efficacy of Piperacillin can be decreased when used in combination with Lymecycline.
DB00415
The therapeutic efficacy of Ampicillin can be decreased when used in combination with Lymecycline.
DB00417
The therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Lymecycline.
DB00485
The therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Lymecycline.
DB00578
The therapeutic efficacy of Carbenicillin can be decreased when used in combination with Lymecycline.
DB00607
The therapeutic efficacy of Nafcillin can be decreased when used in combination with Lymecycline.
DB00713
The therapeutic efficacy of Oxacillin can be decreased when used in combination with Lymecycline.
DB00739
The therapeutic efficacy of Hetacillin can be decreased when used in combination with Lymecycline.
DB00895
The therapeutic efficacy of Benzylpenicilloyl polylysine can be decreased when used in combination with Lymecycline.
DB00948
The therapeutic efficacy of Mezlocillin can be decreased when used in combination with Lymecycline.
DB01000
The therapeutic efficacy of Cyclacillin can be decreased when used in combination with Lymecycline.
DB01053
The therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Lymecycline.
DB01060
The therapeutic efficacy of Amoxicillin can be decreased when used in combination with Lymecycline.
DB01061
The therapeutic efficacy of Azlocillin can be decreased when used in combination with Lymecycline.
DB01147
The therapeutic efficacy of Cloxacillin can be decreased when used in combination with Lymecycline.
DB01163
The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Lymecycline.
DB01602
The therapeutic efficacy of Bacampicillin can be decreased when used in combination with Lymecycline.
DB01603
The therapeutic efficacy of Meticillin can be decreased when used in combination with Lymecycline.
DB01604
The therapeutic efficacy of Pivampicillin can be decreased when used in combination with Lymecycline.
DB01605
The therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Lymecycline.
DB01607
The therapeutic efficacy of Ticarcillin can be decreased when used in combination with Lymecycline.
DB08795
The therapeutic efficacy of Azidocillin can be decreased when used in combination with Lymecycline.
DB09319
The therapeutic efficacy of Carindacillin can be decreased when used in combination with Lymecycline.
DB09320
The therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Lymecycline.
DB12127
The therapeutic efficacy of Sultamicillin can be decreased when used in combination with Lymecycline.
DB12343
The therapeutic efficacy of Temocillin can be decreased when used in combination with Lymecycline.
DB13300
The therapeutic efficacy of Epicillin can be decreased when used in combination with Lymecycline.
DB13337
The therapeutic efficacy of Pheneticillin can be decreased when used in combination with Lymecycline.
DB13506
The therapeutic efficacy of Carfecillin can be decreased when used in combination with Lymecycline.
DB13660
The therapeutic efficacy of Propicillin can be decreased when used in combination with Lymecycline.
DB13686
The therapeutic efficacy of Clometocillin can be decreased when used in combination with Lymecycline.
DB13693
The therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Lymecycline.
DB13739
The therapeutic efficacy of Penamecillin can be decreased when used in combination with Lymecycline.
DB13814
The therapeutic efficacy of Talampicillin can be decreased when used in combination with Lymecycline.
DB13816
The therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Lymecycline.
DB13836
The therapeutic efficacy of Metampicillin can be decreased when used in combination with Lymecycline.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lymecycline.
DB09275
The serum concentration of Lymecycline can be decreased when it is combined with Bismuth subcitrate potassium.
DB09267
The serum concentration of Lymecycline can be decreased when it is combined with Strontium ranelate.
DB00326
The serum concentration of Lymecycline can be decreased when it is combined with Calcium glucoheptonate.
DB13142
The serum concentration of Lymecycline can be decreased when it is combined with Calcium glubionate anhydrous.
DB11126
The serum concentration of Lymecycline can be decreased when it is combined with Calcium gluconate.
DB11093
The serum concentration of Lymecycline can be decreased when it is combined with Calcium citrate.
DB11348
The serum concentration of Lymecycline can be decreased when it is combined with Calcium Phosphate.
DB13231
The serum concentration of Lymecycline can be decreased when it is combined with Calcium lactate.
DB13365
The serum concentration of Lymecycline can be decreased when it is combined with Calcium lactate gluconate.
DB13590
The serum concentration of Lymecycline can be decreased when it is combined with Calcium pangamate.
DB13800
The serum concentration of Lymecycline can be decreased when it is combined with Calcium levulinate.
DB00258
The serum concentration of Lymecycline can be decreased when it is combined with Calcium acetate.
DB01164
The serum concentration of Lymecycline can be decreased when it is combined with Calcium chloride.
DB06724
The serum concentration of Lymecycline can be decreased when it is combined with Calcium carbonate.
DB01373
The serum concentration of Lymecycline can be decreased when it is combined with Calcium.
DB14577
The serum concentration of Lymecycline can be decreased when it is combined with Calcium cation.
DB14684
The serum concentration of Lymecycline can be decreased when it is combined with Calcium polycarbophil.
DB00375
Colestipol can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00930
Colesevelam can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01432
Cholestyramine can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00658
Sevelamer can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00653
Magnesium sulfate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01377
Magnesium oxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01397
Magnesium salicylate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08938
Magaldrate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09104
Magnesium hydroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09281
Magnesium trisilicate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09407
Magnesium chloride can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09481
Magnesium carbonate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11110
Magnesium citrate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13249
Magnesium silicate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13322
Hydrotalcite can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13359
Magnesium aspartate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13486
Magnesium peroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13749
Magnesium gluconate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13786
Magnesium orotate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14514
Magnesium levulinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14515
Magnesium lactate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06723
Aluminum hydroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01370
Aluminium can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13209
Bismuth subnitrate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13280
Aluminium acetoacetate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13595
Almasilate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13626
Aluminium glycinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13650
Aloglutamol can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13829
Calcium silicate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01390
Sodium bicarbonate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14517
Aluminium phosphate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01593
Zinc can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB02165
Zinc trihydroxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB04249
Zinc Substituted Heme C can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09221
Polaprezinc can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09321
Zinc oxide can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09322
Zinc sulfate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11154
Zinc citrate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11175
Zinc picolinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11248
Zinc gluconate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14479
Acetylcysteine zinc can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14485
Zinc ascorbate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14487
Zinc acetate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14493
Zinc glycinate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14533
Zinc chloride can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14548
Zinc sulfate, unspecified form can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14532
Zinc cation can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06792
The serum concentration of Lymecycline can be decreased when it is combined with Lanthanum carbonate.
DB00893
Lymecycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01592
Lymecycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06783
Lymecycline can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09147
Lymecycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09501
Lymecycline can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09507
Lymecycline can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09508
Lymecycline can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11171
Lymecycline can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11210
Lymecycline can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11417
Lymecycline can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11576
Lymecycline can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12821
Lymecycline can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13257
Lymecycline can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13381
Lymecycline can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13423
Lymecycline can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13949
Lymecycline can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14488
Lymecycline can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14489
Lymecycline can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14491
Lymecycline can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14520
Lymecycline can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14695
Lymecycline can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB15598
Lymecycline can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lymecycline.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Lymecycline.
DB00294
The serum concentration of Etonogestrel can be decreased when it is combined with Lymecycline.
DB00304
The serum concentration of Desogestrel can be decreased when it is combined with Lymecycline.
DB00351
The serum concentration of Megestrol acetate can be decreased when it is combined with Lymecycline.
DB00367
The serum concentration of Levonorgestrel can be decreased when it is combined with Lymecycline.
DB00378
The serum concentration of Dydrogesterone can be decreased when it is combined with Lymecycline.
DB00396
The serum concentration of Progesterone can be decreased when it is combined with Lymecycline.
DB00603
The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lymecycline.
DB00717
The serum concentration of Norethisterone can be decreased when it is combined with Lymecycline.
DB00823
The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lymecycline.
DB00957
The serum concentration of Norgestimate can be decreased when it is combined with Lymecycline.
DB01395
The serum concentration of Drospirenone can be decreased when it is combined with Lymecycline.
DB01431
The serum concentration of Allylestrenol can be decreased when it is combined with Lymecycline.
DB04839
The serum concentration of Cyproterone acetate can be decreased when it is combined with Lymecycline.
DB06713
The serum concentration of Norelgestromin can be decreased when it is combined with Lymecycline.
DB06730
The serum concentration of Gestodene can be decreased when it is combined with Lymecycline.
DB06789
The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Lymecycline.
DB09123
The serum concentration of Dienogest can be decreased when it is combined with Lymecycline.
DB09124
The serum concentration of Medrogestone can be decreased when it is combined with Lymecycline.
DB09371
The serum concentration of Norethynodrel can be decreased when it is combined with Lymecycline.
DB09389
The serum concentration of Norgestrel can be decreased when it is combined with Lymecycline.
DB11372
The serum concentration of Altrenogest can be decreased when it is combined with Lymecycline.
DB11619
The serum concentration of Gestrinone can be decreased when it is combined with Lymecycline.
DB11636
The serum concentration of Nomegestrol can be decreased when it is combined with Lymecycline.
DB12474
The serum concentration of Lynestrenol can be decreased when it is combined with Lymecycline.
DB13230
The serum concentration of Gestonorone can be decreased when it is combined with Lymecycline.
DB13528
The serum concentration of Chlormadinone can be decreased when it is combined with Lymecycline.
DB13533
The serum concentration of Methylestrenolone can be decreased when it is combined with Lymecycline.
DB13563
The serum concentration of Norgestrienone can be decreased when it is combined with Lymecycline.
DB13602
The serum concentration of Promegestone can be decreased when it is combined with Lymecycline.
DB13685
The serum concentration of Quingestanol can be decreased when it is combined with Lymecycline.
DB13857
The serum concentration of Demegestone can be decreased when it is combined with Lymecycline.
DB13866
The serum concentration of Etynodiol can be decreased when it is combined with Lymecycline.
DB13981
The serum concentration of Nomegestrol acetate can be decreased when it is combined with Lymecycline.
DB14570
The serum concentration of Hydroxyprogesterone can be decreased when it is combined with Lymecycline.
DB14678
The serum concentration of Norethindrone enanthate can be decreased when it is combined with Lymecycline.
DB14679
The serum concentration of Quingestanol acetate can be decreased when it is combined with Lymecycline.
DB09139
Lymecycline may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
DB00091
The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Lymecycline.
DB00254
The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Lymecycline.
DB00314
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Capreomycin.
DB00452
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Framycetin.
DB00453
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Clomocycline.
DB00468
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Quinine.
DB00512
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Vancomycin.
DB00560
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Tigecycline.
DB00595
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Oxytetracycline.
DB00608
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Chloroquine.
DB00618
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Demeclocycline.
DB00684
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Tobramycin.
DB00759
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Tetracycline.
DB00798
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Gentamicin.
DB00903
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Etacrynic acid.
DB00908
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Quinidine.
DB00931
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Metacycline.
DB00955
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Netilmicin.
DB00994
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Neomycin.
DB01017
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Minocycline.
DB01035
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Procainamide.
DB01082
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Streptomycin.
DB01111
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Colistimethate.
DB01172
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Kanamycin.
DB01190
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Clindamycin.
DB01219
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Dantrolene.
DB01301
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Rolitetracycline.
DB01378
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium cation.
DB01421
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Paromomycin.
DB01627
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Lincomycin.
DB03615
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Ribostamycin.
DB04263
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Geneticin.
DB04626
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Apramycin.
DB04729
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Gentamicin C1a.
DB04808
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Neamine.
DB06696
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Arbekacin.
DB06827
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Viomycin.
DB08437
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Puromycin.
DB09409
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium acetate tetrahydrate.
DB11189
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium glycinate.
DB11230
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium Aluminum Silicate.
DB11512
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Dihydrostreptomycin.
DB11520
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Hygromycin B.
DB12604
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Sisomicin.
DB12615
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Plazomicin.
DB13264
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Penimepicycline.
DB13540
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Isepamicin.
DB13862
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium phosphate.
DB13996
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium acetate.
DB14077
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Magnesium stearate.
DB00803
The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Colistin.
DB00042
The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum Toxin Type B.
DB00083
The risk or severity of adverse effects can be increased when Lymecycline is combined with Botulinum toxin type A.
DB00184
The risk or severity of adverse effects can be increased when Lymecycline is combined with Nicotine.
DB01090
The risk or severity of adverse effects can be increased when Lymecycline is combined with Pentolinium.
DB01116
The risk or severity of adverse effects can be increased when Lymecycline is combined with Trimethaphan.
DB08960
The risk or severity of adverse effects can be increased when Lymecycline is combined with Hexamethonium.
DB08999
The risk or severity of adverse effects can be increased when Lymecycline is combined with Cyclopentamine.
DB00266
The risk or severity of bleeding can be increased when Lymecycline is combined with Dicoumarol.
DB00498
The risk or severity of bleeding can be increased when Lymecycline is combined with Phenindione.
DB00682
The risk or severity of bleeding can be increased when Lymecycline is combined with Warfarin.
DB00946
The risk or severity of bleeding can be increased when Lymecycline is combined with Phenprocoumon.
DB01418
The risk or severity of bleeding can be increased when Lymecycline is combined with Acenocoumarol.
DB03410
The risk or severity of bleeding can be increased when Lymecycline is combined with 4-hydroxycoumarin.
DB04665
The risk or severity of bleeding can be increased when Lymecycline is combined with Coumarin.
DB08496
The risk or severity of bleeding can be increased when Lymecycline is combined with (R)-warfarin.
DB08794
The risk or severity of bleeding can be increased when Lymecycline is combined with Ethyl biscoumacetate.
DB13136
The risk or severity of bleeding can be increased when Lymecycline is combined with Fluindione.
DB13275
The risk or severity of bleeding can be increased when Lymecycline is combined with Clorindione.
DB13347
The risk or severity of bleeding can be increased when Lymecycline is combined with Diphenadione.
DB13451
The risk or severity of bleeding can be increased when Lymecycline is combined with Tioclomarol.
DB14055
The risk or severity of bleeding can be increased when Lymecycline is combined with (S)-Warfarin.
DB04272
The therapeutic efficacy of Lymecycline can be decreased when used in combination with Citric acid.
DB09125
The therapeutic efficacy of Lymecycline can be decreased when used in combination with Potassium citrate.
DB09154
The therapeutic efficacy of Lymecycline can be decreased when used in combination with Sodium citrate.
DB09459
The therapeutic efficacy of Lymecycline can be decreased when used in combination with L-tartaric acid.
DB00390
Lymecycline can cause an increase in the absorption of Digoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
DB13401
Lymecycline can cause an increase in the absorption of Metildigoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
DB13691
Lymecycline can cause an increase in the absorption of Acetyldigoxin resulting in an increased serum concentration and potentially a worsening of adverse effects.
DB00255
The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lymecycline.
DB00783
The serum concentration of Estradiol can be decreased when it is combined with Lymecycline.
DB00834
The serum concentration of Mifepristone can be decreased when it is combined with Lymecycline.
DB00977
The serum concentration of Ethinylestradiol can be decreased when it is combined with Lymecycline.
DB01357
The serum concentration of Mestranol can be decreased when it is combined with Lymecycline.
DB04066
The serum concentration of p-Coumaric acid can be decreased when it is combined with Lymecycline.
DB04574
The serum concentration of Estrone sulfate can be decreased when it is combined with Lymecycline.
DB04682
The serum concentration of Octylphenoxy polyethoxyethanol can be decreased when it is combined with Lymecycline.
DB05830
The serum concentration of Trestolone can be decreased when it is combined with Lymecycline.
DB06266
The serum concentration of Lonidamine can be decreased when it is combined with Lymecycline.
DB08867
The serum concentration of Ulipristal can be decreased when it is combined with Lymecycline.
DB09401
The serum concentration of Isosorbide can be decreased when it is combined with Lymecycline.
DB11507
The serum concentration of Cloprostenol can be decreased when it is combined with Lymecycline.
DB12025
The serum concentration of Triptolide can be decreased when it is combined with Lymecycline.
DB13044
The serum concentration of Gossypol can be decreased when it is combined with Lymecycline.
DB13310
The serum concentration of Ormeloxifene can be decreased when it is combined with Lymecycline.
DB13944
The serum concentration of Testosterone enanthate can be decreased when it is combined with Lymecycline.
DB13953
The serum concentration of Estradiol benzoate can be decreased when it is combined with Lymecycline.
DB13954
The serum concentration of Estradiol cypionate can be decreased when it is combined with Lymecycline.
DB13956
The serum concentration of Estradiol valerate can be decreased when it is combined with Lymecycline.
DB00563
Lymecycline can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Lymecycline.
DB01028
The risk or severity of renal failure can be increased when Methoxyflurane is combined with Lymecycline.
DB14513
Magnesium can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Lymecycline.
DB00162
The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Lymecycline.
DB00307
The risk or severity of pseudotumor cerebri can be increased when Bexarotene is combined with Lymecycline.
DB00459
The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Lymecycline.
DB00523
The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Lymecycline.
DB00755
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Lymecycline.
DB00799
The risk or severity of pseudotumor cerebri can be increased when Tazarotene is combined with Lymecycline.
DB00926
The risk or severity of pseudotumor cerebri can be increased when Etretinate is combined with Lymecycline.
DB00982
The risk or severity of pseudotumor cerebri can be increased when Isotretinoin is combined with Lymecycline.
DB02699
The risk or severity of pseudotumor cerebri can be increased when 4-Oxoretinol is combined with Lymecycline.
DB05076
The risk or severity of pseudotumor cerebri can be increased when Fenretinide is combined with Lymecycline.
DB08455
The risk or severity of pseudotumor cerebri can be increased when Ro 12-7310 is combined with Lymecycline.
DB12112
The risk or severity of pseudotumor cerebri can be increased when Zuretinol acetate is combined with Lymecycline.
DB13368
The risk or severity of pseudotumor cerebri can be increased when Motretinide is combined with Lymecycline.
DB00900
Didanosine can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00237
The metabolism of Lymecycline can be increased when combined with Butabarbital.
DB00241
The metabolism of Lymecycline can be increased when combined with Butalbital.
DB00312
The metabolism of Lymecycline can be increased when combined with Pentobarbital.
DB00418
The metabolism of Lymecycline can be increased when combined with Secobarbital.
DB00474
The metabolism of Lymecycline can be increased when combined with Methohexital.
DB00599
The metabolism of Lymecycline can be increased when combined with Thiopental.
DB00794
The metabolism of Lymecycline can be increased when combined with Primidone.
DB00849
The metabolism of Lymecycline can be increased when combined with Methylphenobarbital.
DB01154
The metabolism of Lymecycline can be increased when combined with Thiamylal.
DB01174
The metabolism of Lymecycline can be increased when combined with Phenobarbital.
DB01351
The metabolism of Lymecycline can be increased when combined with Amobarbital.
DB01355
The metabolism of Lymecycline can be increased when combined with Hexobarbital.
DB01483
The metabolism of Lymecycline can be increased when combined with Barbital.
DB09001
The metabolism of Lymecycline can be increased when combined with Barbexaclone.
DB00252
The metabolism of Lymecycline can be increased when combined with Phenytoin.
DB01320
The metabolism of Lymecycline can be increased when combined with Fosphenytoin.
DB00564
The metabolism of Lymecycline can be increased when combined with Carbamazepine.
DB00048
The therapeutic efficacy of Collagenase clostridium histolyticum can be decreased when used in combination with Lymecycline.

序列

实验性质

Melting Point
192.5
https://m.chemicalbook.com/ProductChemicalPropertiesCB2891297_EN.htm
Boiling Point
928.1±65.0
http://www.chemspider.com/Chemical-Structure.20121315.html
logP
-1.70
http://www.chemspider.com/Chemical-Structure.20121315.html
pKa
2.50±0.24
https://m.chemicalbook.com/ProductChemicalPropertiesCB2891297_EN.htm

外部标识符

resource：ChEBI
identifier：59040
resource：PubChem Compound
identifier：54707177
resource：PubChem Substance
identifier：46505518
resource：KEGG Drug
identifier：D06884
resource：ChemSpider
identifier：20121315
resource：PharmGKB
identifier：PA164747190
resource：Therapeutic Targets Database
identifier：DAP000881
resource：Wikipedia
identifier：Lymecycline
resource：ChEMBL
identifier：CHEMBL2103929
resource：ZINC
identifier：ZINC000053682936
resource：RxCUI
identifier：6513

外部链接

路径

smpdb-id:SMP0000295
name:Lymecycline Action Pathway
category:drug_action
drugbank-id:DB00117
name:Histidine
drugbank-id:DB00131
name:Adenosine phosphate
drugbank-id:DB00134
name:Methionine
drugbank-id:DB00149
name:Leucine
drugbank-id:DB00156
name:Threonine
drugbank-id:DB00160
name:Alanine
drugbank-id:DB00161
name:Valine
drugbank-id:DB00167
name:Isoleucine
drugbank-id:DB00171
name:ATP
drugbank-id:DB00172
name:Proline
drugbank-id:DB00174
name:Asparagine
drugbank-id:DB00256
name:Lymecycline
drugbank-id:DB01972
name:Guanosine-5'-Monophosphate
drugbank-id:DB02431
name:Cytidine-5'-Triphosphate
drugbank-id:DB03685
name:Uridine monophosphate
drugbank-id:DB03929
name:D-Serine
drugbank-id:DB04160
name:Pyrophosphoric acid

目标

id:BE0000019
name:30S ribosomal protein S4
organism:Escherichia coli (strain K12)
action:inhibitor
Chopra I, Roberts M: Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents.
Chukwudi CU: rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4433-41. doi: 10.1128/AAC.00594-16. Print 2016 Aug.
known-action:yes
name:30S ribosomal protein S4
general-function:Translation repressor activity, nucleic acid binding
specific-function:One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in translational accuracy; many suppressors of streptomycin-dependent mutants of protein S12 are found in this protein, some but not all of which decrease translational accuracy (ram, ribosomal ambiguity mutations).Plays a role in mRNA unwinding by the ribosome, possibly by forming part of a processivity clamp.Protein S4 is also a translational repressor protein, it controls the translation of the alpha-operon (which codes for S13, S11, S4, RNA polymerase alpha subunit, and L17) by binding to its mRNA.Also functions as a rho-dependent antiterminator of rRNA transcription, increasing the synthesis of rRNA under conditions of excess protein, allowing a more rapid return to homeostasis. Binds directly to RNA polymerase.
gene-name:rpsD
locus:
cellular-location:Cytoplasmic
transmembrane-regions:
signal-regions:
theoretical-pi:10.66
molecular-weight:23468.915
chromosome-location:
organism:Escherichia coli (strain K12)
external-identifiers:GenBank Gene DatabaseX02543GenBank Protein Database42798UniProtKBP0A7V8UniProt AccessionRS4_ECOLI
synonyms:ramA
amino-acid-sequence:>lcl|BSEQ0009877|30S ribosomal protein S4 MARYLGPKLKLSRREGTDLFLKSGVRAIDTKCKIEQAPGQHGARKPRLSDYGVQLREKQK VRRIYGVLERQFRNYYKEAARLKGNTGENLLALLEGRLDNVVYRMGFGATRAEARQLVSH KAIMVNGRVVNIASYQVSPNDVVSIREKAKKQSRVKAALELAEQREKPTWLEVDAGKMEG TFKRKPERSDLSADINEHLIVELYSK
gene-sequence:>lcl|BSEQ0009878|30S ribosomal protein S4 (rpsD) ATGGCAAGATATTTGGGTCCTAAGCTCAAGCTGAGCCGTCGTGAGGGCACCGACTTATTC CTTAAGTCTGGCGTTCGCGCGATCGATACCAAGTGTAAAATTGAACAAGCTCCTGGCCAG CACGGTGCGCGTAAACCGCGTCTGTCTGACTATGGTGTGCAGTTGCGTGAAAAGCAAAAA GTTCGCCGTATCTATGGTGTGCTGGAGCGTCAGTTCCGTAACTACTACAAAGAAGCAGCA CGTCTGAAAGGCAACACCGGTGAAAACCTGTTGGCTCTGCTGGAAGGTCGTCTGGACAAC GTTGTATACCGTATGGGCTTCGGTGCCACTCGTGCAGAAGCACGTCAGCTGGTTAGCCAT AAAGCAATTATGGTAAACGGTCGTGTTGTTAACATCGCTTCTTATCAGGTTAGTCCGAAT GACGTTGTAAGCATTCGTGAGAAAGCGAAGAAGCAGTCTCGCGTGAAAGCCGCTCTGGAG CTGGCTGAGCAGCGTGAAAAGCCAACCTGGCTGGAAGTTGATGCTGGCAAGATGGAAGGT ACGTTTAAGCGTAAGCCGGAGCGTTCTGATCTGTCTGCGGACATTAACGAACACCTGATC GTCGAGCTTTACTCCAAGTAA
pfams:PF00163Ribosomal_S4PF01479S4
go-classifiers:componentcytosolcomponentcytosolic small ribosomal subunitfunctionmRNA 5'-UTR bindingfunctionrRNA bindingfunctionstructural constituent of ribosomefunctiontranslation repressor activity, nucleic acid bindingprocessDNA-templated transcription, terminationprocessmaintenance of translational fidelityprocessnegative regulation of translational initiationprocesspositive regulation of translational fidelityprocessresponse to antibioticprocesstranscription antitermination

酶

载体

运输工具

药物反应

效应

不良反应